Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Imprimis Pharmaceuticals Inc    

IMPRIMIS PHARMACEUTICALS INC

My previous session
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

HARROW HEALTH, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2018 | 07:03am EST

Item 5.03 Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.




Name Change



On December 27, 2018, Harrow Health, Inc. (formerly, Imprimis Pharmaceuticals, Inc.) (the "Company") amended its restated certificate of incorporation ("Amendment") to change its corporate name from "Imprimis Pharmaceuticals, Inc." to "Harrow Health, Inc."

The name change was previously approved by the Board of Directors. The shareholders, under Delaware General Corporation Law, were not required to approve the name change.

The stockholders do not need to take any action as a result of the name change, including that there is no need to exchange their certificates representing their shares of common stock. The current stock certificate will continue to represent their ownership interest in the Company. Stockholders, however, may return their certificates to the transfer agent for the Company and obtain an updated certificate.

A copy of the Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K.

The press release relating to the name change being completed and reflected on The NASDAQ Capital Market is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.



Item 8.01 Other Events



Symbol Change


The trading symbol reflecting the new name for the company, for the common stock of the Company, on The NASDAQ Capital Market is HROW.

Item 9.01. Financial Statements and Exhibits



(d)    Exhibits

Item   Description

3.1      Amendment to the Restated Certificate of Incorporation for the name
       change, filed as of December 27, 2018

99.1     Press Release issued by Harrow Health, Inc. on December 31, 2018

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPRIMIS PHARMACEUTICALS I
02/13Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain an..
GL
02/07HARROW HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
02/07Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented D..
GL
02/06HARROW HEALTH : Announces $11 Million Series A Financing for Melt Pharmaceutical..
AQ
02/05HARROW HEALTH, INC. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
02/05Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceutica..
GL
2018HARROW HEALTH, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
2018IMPRIMIS PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Chang..
AQ
2018Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America..
GL
2018IMPRIMIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
AQ
More news
Chart IMPRIMIS PHARMACEUTICALS INC
Duration : Period :
Imprimis Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Mark L. Baum Chief Executive Office & Director
Robert J. Kammer Chairman
Andrew R. Boll CFO, Secretary & Principal Accounting Officer
David Moufarrege Vice President-Technology
Stephen G. Austin Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IMPRIMIS PHARMACEUTICALS INC5.45%147
GILEAD SCIENCES6.73%84 797
VERTEX PHARMACEUTICALS13.49%46 801
REGENERON PHARMACEUTICALS13.51%44 945
GENMAB0.94%10 072
SAREPTA THERAPEUTICS INC25.12%9 627